Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Eleven acquires Viventia Bio; moves into cancer space

Executive Summary

Three months after out-licensing its only development program to Roche, Eleven Biotherapeutics Inc. made a strategic move into the cancer space through the acquisition of private oncology biotech Viventia Bio Inc.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Payment Includes Stock
    • Intra-Biotech Deal
    • Acquisition of Private Biotech
    • Includes Contract
    • Full Acquisition

Related Companies